Abbasciano V, Graziano L, Arcudi D, Felisatti G, Cavallini A R, Reali M G, Calia N, Campi S, Guglielmini C
Istituto di Patologia Speciale Medica, Università degli Studi di Ferrara, Italy.
Med Oncol Tumor Pharmacother. 1991;8(1):29-34. doi: 10.1007/BF02988568.
Serum thymidine-kinase (sTK) was assayed in 48 males affected by small cell carcinoma of the lung (SCCL) at the time of diagnosis. On the same drawing carcinoembryonic antigen (CEA) and beta 2microglobulin (beta 2 microG) were assayed in 19 of these subjects. For staging, the criterion of limited (LD) and extensive (ED) disease was used. Mean sTK and CEA values were above normal range in both the LD and ED groups, while mean beta 2 microG value remained below normal range. Thirty-two patients were subsequently submitted to therapy; sTK was assayed at the end of each treatment cycle. Mean sTK concentrations differed depending on response to therapy. From the data obtained it is concluded that sTK assay is helpful for diagnosis of SCCL; CEA to a lesser extent, above all in association with sTK, and beta microG not at all. sTK assay can also be useful for prognosis and follow-up.
在48例男性肺癌小细胞癌（SCCL）患者诊断时检测血清胸苷激酶（sTK）。在其中19例患者中同时检测癌胚抗原（CEA）和β2微球蛋白（β2 microG）。采用疾病局限期（LD）和广泛期（ED）的分期标准。LD组和ED组的sTK和CEA均值均高于正常范围，而β2 microG均值仍低于正常范围。随后32例患者接受治疗；在每个治疗周期结束时检测sTK。sTK的平均浓度因治疗反应而异。从获得的数据得出结论，sTK检测有助于SCCL的诊断；CEA在较小程度上有帮助，尤其是与sTK联合时，而β2 microG则完全没有帮助。sTK检测对预后和随访也可能有用。
